Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study.
Stathopoulos GP, Ardavanis A, Papakotoulas P, Pectasides D, Papadopoulos G, Antoniou D, Athanasiadis A, Trafalis D, Anagnostopoulos A, Koutantos J, Vaslamatzis M.
Stathopoulos GP, et al.
Anticancer Drugs. 2010 Feb;21(2):202-5. doi: 10.1097/CAD.0b013e3283350092.
Anticancer Drugs. 2010.
PMID: 20010424
Clinical Trial.